<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00033436</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069283</org_study_id>
    <secondary_id>MTVERNHOSP-BCON</secondary_id>
    <secondary_id>EU-20051</secondary_id>
    <nct_id>NCT00033436</nct_id>
  </id_info>
  <brief_title>Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer</brief_title>
  <official_title>A Multicenter Randomized Trial of Radical Radiotherapy With Carbogen in the Radical Treatment of Locally Advanced Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mount Vernon Cancer Centre at Mount Vernon Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as&#xD;
      carbogen and niacinamide may make tumor cells more sensitive to radiation therapy. It is not&#xD;
      yet known whether radiation therapy is more effective with or without carbogen and&#xD;
      niacinamide in treating patients who have bladder cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or&#xD;
      without carbogen and niacinamide in treating patients who have locally advanced bladder&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the 6-month cystoscopic response in patients with locally advanced transitional&#xD;
           cell carcinoma of the bladder treated with radical radiotherapy with or without&#xD;
           radiosensitization with carbogen and niacinamide.&#xD;
&#xD;
        -  Compare the local failure-free and overall disease-specific survival of patients treated&#xD;
           with these regimens.&#xD;
&#xD;
        -  Compare the treatment-related morbidity, in particular acute and chronic bowel and&#xD;
           bladder symptoms, in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the quality of life of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment&#xD;
      arms.&#xD;
&#xD;
        -  Arm I: Patients receive radical radiotherapy once daily, 5 days a week, for 4-6.4 weeks.&#xD;
           Patients also receive oral niacinamide once daily 1.5-2 hours before initiation of each&#xD;
           radiotherapy dose and carbogen through a closed breathing system (face mask with a tight&#xD;
           air seal or a mouthpiece with nasal clip) once daily beginning 5 minutes before&#xD;
           initiation and continuing until completion of each radiotherapy dose.&#xD;
&#xD;
        -  Arm II: Patients receive radiotherapy as in arm I. Quality of life is assessed at&#xD;
           baseline; at 4 weeks; at 3, 6, and 12 months; and then annually for 4 years.&#xD;
&#xD;
      Patients are followed at 8 and 12 weeks; at 6, 9, and 12 months; and then every 6 months for&#xD;
      4 years.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 330 patients (165 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2000</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Cystoscopic response at 6 months after initiation radiotherapy</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Local failure-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall disease-specific survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment related morbidity (i.e., acute and chronic bowel and bladder symptoms)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as assessed by FACT-BI scale at baseline, week 4, 3 months, 6 months, 12 months, and yearly thereafter for 5 years</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Bladder Cancer</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>niacinamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carbogen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed transitional cell carcinoma of the bladder&#xD;
&#xD;
               -  Muscle invasive carcinoma (stage T2 or T3) of any grade OR&#xD;
&#xD;
               -  High-grade (G3) superficial bladder carcinoma (T1) OR&#xD;
&#xD;
               -  Prostatic invasion (T4a)&#xD;
&#xD;
          -  No squamous cell carcinoma or adenocarcinoma of the bladder&#xD;
&#xD;
          -  No locally advanced T4b carcinoma&#xD;
&#xD;
          -  No distant metastasis or enlarged pelvic lymph nodes on CT staging scan of the pelvis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2 times normal&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No ischemic heart disease or peripheral vascular disease requiring diuretics or&#xD;
             angiotensin-converting enzyme inhibitors&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No concurrent respiratory disease with reduced respiratory drive that would preclude&#xD;
             the delivery of 95% oxygen&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Capable of complying with a closed breathing system delivering carbogen through either&#xD;
             a mask or a mouthpiece with nasal clip&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter J. Hoskin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mount Vernon Cancer Centre at Mount Vernon Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sussex Cancer Centre at Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <state>England</state>
        <zip>BN2 5BF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology and Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kent and Canterbury Hospital</name>
      <address>
        <city>Canterbury</city>
        <state>England</state>
        <zip>CT2 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derbyshire Royal Infirmary</name>
      <address>
        <city>Derby</city>
        <state>England</state>
        <zip>DE1 2QY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ipswich Hospital NHS Trust</name>
      <address>
        <city>Ipswich</city>
        <state>England</state>
        <zip>IP4 5PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cookridge Hospital at Leeds Teaching Hospital NHS Trust</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS16 6QB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital NHS Trust</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Centre for Oncology NHS Trust</name>
      <address>
        <city>Merseyside</city>
        <state>England</state>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Centre for Cancer Treatment at Newcastle General Hospital</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE4 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Cancer Centre at Mount Vernon Hospital</name>
      <address>
        <city>Northwood</city>
        <state>England</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oldchurch Hospital</name>
      <address>
        <city>Romford</city>
        <state>England</state>
        <zip>RM7 OBE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research Centre at Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S1O 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Center at Velindre Hospital</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Hoskin PJ, Rojas AM, Saunders MI, Bentzen SM, Motohashi KJ; BCON investigators. Carbogen and nicotinamide in locally advanced bladder cancer: early results of a phase-III randomized trial. Radiother Oncol. 2009 Apr;91(1):120-5. doi: 10.1016/j.radonc.2008.10.001. Epub 2008 Nov 5.</citation>
    <PMID>18992952</PMID>
  </results_reference>
  <verification_date>December 2002</verification_date>
  <study_first_submitted>April 9, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 19, 2013</last_update_submitted>
  <last_update_submitted_qc>September 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <keyword>stage I bladder cancer</keyword>
  <keyword>stage II bladder cancer</keyword>
  <keyword>stage III bladder cancer</keyword>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

